


Company Profile

Omni Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

Our flagship technology, GlucoSmooth™, is a patented pre-meal drink that smooths out the blood glucose spike after a meal for people with type 2 diabetes and pre-diabetes.



The Company licensed this technology in Australia and New Zealand to Faulding® be sold under the tradename GlucoControl™ for use in the dietary management of type 2 diabetes and pre-diabetes. Faulding® GlucoControl™ was launched in Australia during August 2016 and is now available nationally through pharmacies.

Commercial discussions for the GlucoSmooth™ technology are in progress in a number of significant global markets globally including the US, UK and China.

Type 2 diabetes is one of Australia's most prevalent and fast growing chronic diseases. More than 250 Australian's develop the condition every day. Over 1 million Australians currently have type 2 diabetes and an additional 1.5 million have pre-diabetes. Globally over 380 million people have type 2 diabetes – not including more than 2 times this many with pre-diabetes. China alone has more than 200 million people with diabetes or pre-diabetes.

Clinical testing and validation of the GlucoSmooth™ technology was conducted at The Baker IDI Heart and Diabetes Institute in Melbourne, Australia www.bakeridi.edu.au under the supervision of Professor Peter Clifton.

Omni Innovation currently have programs developing further evidence based dietary interventions in various levels of clinical progress and commercialisation.

Please visit www.obinnovation.com.au